# Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study

> **NCT02620618** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cairo University** · enrollment: 20 (actual)

## Conditions studied

- Behçet's Disease
- Uveitis

## Interventions

- **DRUG:** Intravitreal Infliximab

## Key facts

- **NCT ID:** NCT02620618
- **Lead sponsor:** Cairo University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02620618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02620618, "Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02620618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*